イデベノン
アバン · 2,3-ジメトキシ-5-メチル-6-(10-ヒドロキシデシル)-1,4-ベンゾキノン · 6-(10-ヒドロキシデシル)-2,3-ジメトキシ-5-メチル-1,4-ベンゾキノン · 6-(10-ヒドロキシデシル)-2,3-ジメトキシ-5-メチル-2,5-シクロヘキサジエン-1,4-ジオン · イデベノン · 2-(10-ヒドロキシデシル)-5,6-ジメトキシ-3-メチル-1,4-ベンゾキノン · 6-(10-ヒドロキシデシル)-5-メチル-2,3-ジメトキシ-1,4-ベンゾキノン · 2-(10-ヒドロキシデシル)-5,6-ジメトキシ-3-メチル-2,5-シクロヘキサジエン-1,4-ジオン
識別子と物理属性
| CAS No. | 58186-27-9 |
|---|---|
| 分子式 | C19H30O5 |
| 平均分子量 | 338.4 g/mol |
| 単同位体質量 | 338.20932405 g/mol |
| SMILES | COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |
| InChIKey | JGPMMRGNQUBGND-UHFFFAOYSA-N |
| PubChem CID | 3686 |
| ChEMBL | CHEMBL252556 |
| ChEBI | CHEBI:31687 |
| EC No. | 814-253-7 |
| DTXSID | DTXSID0040678 |
| 現地名 | イデベノン |
化学・物理的性質
| XLogP | 4.3 |
|---|---|
| 極性表面積 | 72.8 |
| 水素結合供与体数 | 1 |
| 水素結合受容体数 | 5 |
| 回転可能結合数 | 12 |
| 重原子数 | 24 |
| 形式電荷 | 0 |
| 複雑度 | 502 |
| Collision Cross Section | 173.7 Ų [M+H-H2O]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]181.56 Ų [M+Na]+ [CCS Type: TW181.21 Ų [M+K]+ [CCS Type: TW175.92 Ų [M+H]+ [CCS Type: TW178.6 Ų [M+H]+ [CCS Type: TW |
| 融点 | 52-550C |
| 沸点 | 497.3±45.0 °C(Predicted) |
| 密度 | 1.08±0.1 g/cm3(Predicted) |
| 貯蔵条件 | room temp |
| 溶解度 | DMSO に可溶 (最大 25 mg/ml)。 |
| pKa（酸解離定数） | 15.20±0.10(Predicted) |
| 外観・状態 | Solid |
| 色 | オレンジ |
| Merck | 14,4888 |
| 安定性 | -20°C の DMSO 溶液で最大 3 か月間保存できます。 |
| 化粧品成分の機能 | 抗酸化物質 |
| InChI | InChI=1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3 |
| InChIKey | JGPMMRGNQUBGND-UHFFFAOYSA-N |
| SMILES | C1(=O)C(OC)=C(OC)C(=O)C(C)=C1CCCCCCCCCCO |
| LogP（分配係数） | 3.490 (est) |
| CAS データベース | 58186-27-9(CAS DataBase Reference) |
化学的特性
An odorless yellow-orange crystalline solid. It is highly insoluble in water, but can be easily dissolved in chloroform, methanol, or absolute ethanol. It is also soluble in ethyl acetate, but insoluble in n-hexane.
安全性と法規制
| GHS 分類 | This chemical does not meet GHS hazard criteria for 25% (1 of 4) of reports.DangerH228 (25%): Flammable solid [Danger Flammable solids]H302 (25%): Harmful if swallowed [Warning Acute toxicity, oral]H315 (25%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (25%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H335 (25%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]P210, P240, P241, P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P370+P378, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 4 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Reported as not meeting GHS hazard criteria per 1 of 4 reports by companies.There are 3 notifications provided by 3 of 4 reports by companies with hazard statement code(s).Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| Hazard Classes and Categories | Flam. Sol. 2 (25%)Acute Tox. 4 (25%)Skin Irrit. 2 (25%)Eye Irrit. 2A (25%)STOT SE 3 (25%) |
| 毒性の概要 | Safe in the present practices of use and concentration. Ingredient, concentration, and use information are available in documents discoverable at https://cir-reports.cir-safety.org |
| 水環境危害等級（WGK） | 3 |
| RTECS 番号 | GU5290000 |
| 税関コード | 2933399990 |
| 危険表示 | Xi |
用途
用途
薬理研究用。
説明
Idebenone is an organic compound belonging to the quinone family, being similar to coenzyme Q-10. It is a kind of drug developed by Takeda Pharmaceutical Company for the treatment of Alzheimer’s disease and some other cognitive defects. However, these have been not very much progress associated with this indication. It is now also used for the treatment of Friedreich’s ataxia with a positive effect on cardiac hypertrophy and neurological function. However, this indication is only approved in Canada, not in Europe and US. It is now under investigation on its efficacy for the treatment of Duchenne muscular dystrophy, Leber’s hereditary optic neuropathy, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) as well as primary progressive multiple sclerosis. The efficacy of this drug still demands more evidences.
使用
idebenone is an anti-oxidant capable of protecting the skin from a variety of free-radical attacks, including the formation of secondary chemicals that negatively affect skin physiology. It is said to improve intrinsic as well as extrinsic skin damage caused by freeradical formation. Idebenone is a synthetically manufactured form of coenzyme Q10 and has a smaller molecular structure. This allows it to penetrate the skin and apparently the cellular membrane. Clinical studies demonstrate a visible improvement in photodamaged skin, reduced skin roughness and dryness, decreased fine lines and wrinkles, and increased skin hydration. In addition, idebenone helps improve hyperpigmentation because its molecular structure is similar to that of hydroquinone. Although most of the associated benefits are seen primarily in the epidermis, some increase in dermal collagen has also been confirmed. Idebenone has been used for such health-related problems as Alzheimer’s and heart disease.
一般的な説明
Idebenone is a short-chain benzoquinone drug. It is a structural relative of ubiquinone (Coenzyme Q10) that protects the CNS from the effects of ischemia via improving brain metabolism. It is reported to be of potential use in the management of patients with cerebral apoplexy, cerebral arteriosclerosis and related disorders.